Daniel R. Chevallard is CFO and COO at Viracta Therapeutics, Inc. (VIRX). They have made 13 open-market trades across 3 companies since 2017, most recently 2026-03-27.
CIK 0001706176
4 open-market purchases totalling $214K since 2017, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RGLS | 77,870 | $635K |
| LENZ | 12,886 | $42K |
| VIRX | 102,306 | $8K |
| Total | $686K |
Shares reported on the most recent Form 4, priced at the 2026-03-30 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LENZ | BUY | 2026-03-27 | 2026-03-30 | $8.57 | $64K | +8.0% | +7.7% | -31.6% |
| LENZ | BUY | 2025-11-07 | 2025-11-07 | $22.76 | $50K | +18.5% | +11.5% | -41.7% |
| LENZ | BUY | 2024-05-14 | 2024-05-15 | $15.68 | $50K | -3.3% | +16.5% | +45.5% |
| VIRX | SELL | 2024-02-27 | 2024-02-27 | $0.73 | $2K | +6.3% | +27.5% | -7.3% |
| VIRX | SELL | 2023-11-28 | 2023-11-28 | $0.50 | $2K | +2.2% | +16.4% | +42.9% |
| VIRX | SELL | 2023-08-28 | 2023-08-29 | $1.45 | $5K | -6.3% | -26.1% | -64.1% |
| VIRX | SELL | 2023-05-25 | 2023-05-26 | $1.42 | $5K | -5.1% | -10.8% | -9.5% |
| VIRX | SELL | 2023-02-27 | 2023-02-28 | $1.68 | $6K | -2.9% | -12.1% | -21.8% |
| VIRX | SELL | 2022-11-28 | 2022-11-29 | $2.72 | $10K | -24.3% | -44.2% | -26.1% |
| VIRX | SELL | 2022-08-26 | 2022-08-29 | $4.02 | $15K | +29.8% | +7.6% | -37.9% |
| VIRX | SELL | 2022-05-26 | 2022-05-27 | $1.90 | $7K | +50.7% | +51.2% | +98.1% |
| VIRX | SELL | 2022-02-28 | 2022-03-01 | $2.78 | $11K | -12.8% | +68.8% | -24.8% |
| RGLS | SELL · 10b5-1 | 2019-07-01 | 2019-07-02 | $1.31 | $3K | -5.3% | -54.6% | -45.9% |
| RGLS | SELL · 10b5-1 | 2019-05-15 | 2019-05-16 | $1.41 | $14K | -1.7% | -17.7% | -52.5% |
| RGLS | SELL · 10b5-1 | 2019-04-01 | 2019-04-03 | $0.98 | $3K | +3.8% | +3.8% | +26.0% |
| RGLS | BUY | 2017-07-25 | 2017-07-25 | $0.91 | $50K | -21.1% | -13.6% | +1.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.